The mds Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mds Hub cannot guarantee the accuracy of translated content. The mds and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View mds content recommended for you
Uma BorateDuring the 25th Congress of the European Hematology Association (EHA), the MDS Hub spoke to Uma Borate, OHSU Knight Cancer Institute, Portland, US. We asked: Is there synergy between anti-TIM-3 and hypomethylating therapy in the treatment of MDS?
Is there synergy between anti-TIM-3 therapy and HMAs in the treatment of MDS?
TIM-3 is a co-inhibitory receptor involved in regulating both innate and adaptive immunity. TIM-3 is expressed on leukemic stem cells and blasts, but is not present on healthy hematopoietic stem cells, making it an attractive target to enhance immune-mediated tumor destruction. Preclinical studies on models of acute myeloid leukemia and MDS have highlighted synergistic activity of anti-TIM-3-targeted antibody therapy and hypomethylating agents.
Uma Borate outlines the progression of this combination into clinical studies.